|
Delayed
Toronto S.E.
09:36:55 2026-07-06 EDT
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | -.--% |
|
-.--% | -40.00% |
| Market Cap | 918K 659K 571K 535K 488K 62.87M 933K 6.3M 2.46M 31.47M 2.47M 2.42M 105M | P/E 2024 |
-40.5x | P/E 2025 | -5.33x |
|---|---|---|---|---|---|
| Enterprise Value | 1.92M 1.38M 1.19M 1.12M 1.02M 131M 1.95M 13.16M 5.14M 65.72M 5.16M 5.05M 219M | EV / Sales 2024 |
929,496,174x | EV / Sales 2025 | - |
| Free-Float |
53.08% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -25.00% | ||
| 6 months | -25.00% | ||
| Current year | -40.00% |
| Current year | 0.02 | 0.02 | |
| 1 year | 0.02 | 0.04 | |
| 3 years | 0.02 | 0.09 | |
| 5 years | 0.02 | 0.2 | |
| 10 years | 0.01 | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
CEO | Chief Executive Officer | 57 | 2018-08-02 |
Mahmoud Aziz
PSD | President | - | 2021-05-20 |
Danny Wayne Lee
DFI | Director of Finance/CFO | - | 2020-12-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
BRD | Director/Board Member | 57 | 2018-08-02 |
Jamie Lewin
BRD | Director/Board Member | 76 | 2019-03-10 |
Kevin Bottomley
BRD | Director/Board Member | 44 | 2019-09-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 9/9/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 9/9/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 9/9/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -57.14% | -75.00% | 660K | ||
| -0.62% | -0.41% | +19.10% | +70.62% | 48.9B | ||
| +1.51% | +5.34% | +57.99% | +122.57% | 40.42B | ||
| -3.13% | +4.12% | +22.15% | +79.32% | 12.6B | ||
| -0.29% | 0.00% | -4.13% | +16.69% | 12.39B | ||
| -2.89% | -0.76% | +30.40% | +135.91% | 9.07B | ||
| -1.77% | +5.96% | +22.02% | +37.63% | 7.53B | ||
| +0.06% | +5.06% | +40.35% | -13.51% | 7.13B | ||
| +1.31% | +2.70% | +12.72% | +189.51% | 6.78B | ||
| +1.45% | +4.22% | -24.30% | +30.37% | 5.83B | ||
| Average | -0.44% | +2.49% | +11.92% | +59.41% | 15.06B | |
| Weighted average by Cap. | -0.23% | +2.37% | +27.74% | +82.94% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.46 | - |
| Net income | -73.2K -52.51K -45.51K -42.66K -38.9K -5.01M -74.37K -502K -196K -2.51M -197K -193K -8.37M | -335K -240K -208K -195K -178K -22.94M -340K -2.3M -898K -11.48M -902K -883K -38.3M |
| Net Debt | 804K 577K 500K 469K 427K 55.06M 817K 5.52M 2.15M 27.56M 2.17M 2.12M 91.93M | 999K 717K 621K 582K 531K 68.41M 1.02M 6.86M 2.68M 34.25M 2.69M 2.63M 114M |
Employees
4,000
Sector
Pharmaceuticals
- Stock Market
- Stocks
- GENX Stock
Select your edition
All financial news and data tailored to specific country editions
















